The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: A systematic review and meta-analysis

Pain Physician

Volumn 18, Issue 2, 2015, Pages 131-152

  Ren, Zhen Yu ^a   Xu, Xiao Qing ^a,c   Bao, Yan Ping ^b   He, Jia ^b   Shi, L ^b   Deng, Jia Hui ^b   Gao, Xue Jiao ^b   Tang, Hui Lin ^a   Wang, Yu Mei ^b   Lu, Lin ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Meta analysis; Opioid; Postoperative pain; Single nucleotide polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN; NARCOTIC ANALGESIC AGENT; SEROTONIN 2A RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VOLTAGE GATED SODIUM CHANNEL; MU OPIATE RECEPTOR; OPRM1 PROTEIN, HUMAN;

ANALGESIA; BIBLIOGRAPHIC DATABASE; DRUG EFFICACY; DRUG SENSITIVITY; GENE; GENETIC VARIABILITY; HUMAN; INFORMATION PROCESSING; META ANALYSIS; MU OPIOID RECEPTOR GENE; NAUSEA AND VOMITING; PAIN ASSESSMENT; POSTOPERATIVE PAIN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; FEMALE; GENETICS; MALE; MIDDLE AGED; PAIN, POSTOPERATIVE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANALGESICS, OPIOID; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; PAIN, POSTOPERATIVE; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU;

EID: 84925302016     PISSN: 15333159     EISSN: 21501149     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. 1. Mercadante S, Bruera E. Opioid switching: A systematic and critical review. Cancer Treat Rev 2006; 32:304-315.
2. Riley J, Ross JR, Rutter D, Wells AU, Goller K, du Bois R, Welsh K. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006; 14:56-64.
3. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du Bois R, Riley J. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5:324-336.
4. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105:334-337.
5. 5. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79:316-324.
6. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109:520-526.
7. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 1999; 96:7752-7755.
8. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: Clinical utility and future perspectives. Clin Pharmacokinet 2004; 43:983-1013.
9. Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, Uhl GR. Mu opiate receptor gene dose effects on different morphine actions: Evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 2001; 25:41-54.
10. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL. Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci U S A 2009; 106:10811-10816.
11. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010; 1187:184-207.
12. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 1994; 338:217-222.
13. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95:9608-9613.
14. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, Mogil JS, Wallace MR. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005; 6:159-167.
15. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48:1232-1239.
16. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008; 139:5-14.
17. Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130:25-30.
18. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83:559-566.
19. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146:270-275.
20. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50:787-792.
21. Liao Q, Chen DJ, Zhang F, Li L, Hu R, Tang YZ, Ou-Yang W, Huang D. Effect of CYP3A4*18B polymorphisms and interactions with OPRM1 A118G on postoperative fentanyl requirements in patients undergoing radical gastrectomy. Molecular Medicine Reports 2013; 7:901-908.
22. Sia AT, Lim Y, Lim EC, Ocampo CE, Lim WY, Cheong P, Tan EC. Influence of muopioid receptor variant on morphine use and self-rated pain following abdominal hysterectomy. J Pain 2013; 14:1045-1052.
23. Zhang F, Liao Q, Li L, Wang SY, Hu R, Tang YZ, Ouyang W. The correlation between post-operative fentanyl requirements and -opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy. Exp Ther Med 2013; 5:1147-1152.
24. Zhang W, Chang YZ, Kan QC, Zhang LR, Lu H, Chu QJ, Wang Z., Li ZS, Zhang J. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 2010; 65:130-135.
25. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol 2011; 77:33-39.
26. Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T, Ruiz-Velasco V, Mets B. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 2006; 103:1011-1017.
27. Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K. Lack of Association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol 2012; 52:234-242.
28. Wu WD, Wang Y, Fang YM, Zhou HY. Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther 2009; 13:331-337.
29. Henker RA, Lewis A, Dai F, Lariviere WR, Meng L, Gruen GS, Sereika SM, Pape H, Tarkin IS, Gowda I, Conley YP. The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol Res Nurs 2013; 15:309-317.
30. Fukuda K, Hayashida M, Ikeda K, Koukita Y, Ichinohe T, Kaneko Y. Diversity of opioid requirements for postoperative pain control following oral surgery – is it affected by polymorphism of the mu-opioid receptor? Anesth Prog 2010; 57:145-149.
31. Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Komatsu H, Sora I, Fukuda K, Koga H, Hanaoka K, Ikeda K. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008; 9:1605-1616.
32. Kim KM, Kim HS, Lim SH, Cheong SH, Choi EJ, Kang H, Choi HR, Jeon JW, Yon JH, Oh M, Shin JG. Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. Int J Clin Pharmacol Ther 2013; 51:383-392.
33. Fukuda K, Hayashida M, Ide S, Saita N, Kokita Y, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Nagashima M, Tagami M, Komatsu H, Sora I, Koga H, Kaneko Y, Ikeda K. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 2009; 147:194-201.
34. De Gregori M, Garbin G, De Gregori S, Minella CE, Bugada D, Lisa A, Govoni S, Regazzi M, Allegri M, Ranzani GN. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharmacol 2013; 69:1651-1658.
35. Boswell MV, Stauble ME, Loyd GE, Langman L, Ramey-Hartung B, Baumgartner RN, Tucker WW, Jortani SA. The role of hydromorphone and OPRM1 in post-operative pain relief with hydrocodone. Pain Physician 2013; 16:E227-E235.
36. Chen LK, Chen SS, Huang CH, Yang HJ, Lin CJ, Chien KL, Fan SZ. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) might not protect against or enhance morphine-induced nausea or vomiting. Pain Res Treat 2013; 2013:259306.
37. Nelson DR. Cytochrome P450 nomenclature, 2004. Methods Mol Biol 2006; 320:1-10.
38. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain 2009; 5:32.
39. Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014; 123:25-33.
40. Adler TK, Fujimoto JM, Way EL, Baker EM. The metabolic fate of codeine in man. J Pharmacol Exp Ther 1955; 114:251-262.
41. Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A 1973; 70:2243-2247.
42. Manini AF, Jacobs MM, Vlahov D, Hurd YL. Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. J Med Toxicol 2013; 9:148-154.
43. Ziesenitz VC, van den Anker JN. Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacody-namics of fentanyl. Int J Clin Pharmacol Ther 2013; 51:991-992.
44. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996; 24:932-939.
45. Chen YT, Tsou HH, Kuo HW, Fang CP, Wang SC, Ho IK, Chang YS, Chen CH, Hsiao CF, Wu HY, Lin KM, Chen A, Tsai-Wu JJ, Liu YL. OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: A cross sectional study. J Hum Genet 2013; 58:84-90.
46. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clinical Pharmacology and Therapeutics 2008; 83:234-242.
47. Persson K, Sjostrom S, Sigurdardottir I, Molnar V, Hammarlund-Udenaes M, Rane A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br J Clin Pharmacol 1995; 39:182-186.
48. 48. VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: A pilot study. Ther Drug Monit 2011; 33:425-432.
49. Ochroch EA, Vachani A, Gottschalk A, Kanetsky PA. Natural variation in the mu-opioid gene OPRM1 predicts increased pain on third day after thoracotomy. Clin J Pain 2012; 28:747-754.
50. Rauers NI, Stuber F, Lee EH, Musshoff F, Fimmers R, Barann M, Stamer UM. Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study. J Pain 2010; 11:1274-1281.
51. Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratisl Lek Listy 2012; 113:152-155.
52. Candiotti KA, Yang Z, Rodriguez Y, Crescimone A, Sanchez GC, Takacs P, Medina C, Zhang Y, Liu H, Gitlin MC. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. Pain Med 2009; 10:799-805.
53. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010; 54:232-240.
54. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991; 27:7-17.
55. Vickers MD, O’Flaherty D, Szekely SM, Read M, Yoshizumi J. Tramadol: Pain relief by an opioid without depression of respiration. Anaesthesia 1992; 47:291-296.
56. Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53:235-239.
57. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60:636-644.
58. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351:2827-2831.
59. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, Stuber F. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105:231-238.
60. Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CY-P2D6 modulation. J Immunol 2005; 175:7357-7362.
61. Yuan R, Zhang X, Deng Q, Wu Y, Xiang G. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clinica Chimica Acta; International Journal of Clinical Chemistry 2011; 412:755-760.
62. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang Z., Li ZS. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. European Journal of Anaesthesiology 2011; 28:245-250.
63. Dong ZL, Li H, Chen QX, Hu Y, Wu SJ, Tang LY, Gong WY, Xie GH, Fang XM. Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population. Journal of Clinical Pharmacy and Therapeutics 2012; 37:153-156.
64. Tan PC, Hassan SK, Mohamad NA, Gan SH. Cytochrome P450 3A4 genetic polymorphisms and post-operative fentanyl requirements. J Clin Pharm Ther 2012; 37:100-104.
65. 65. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1997; 25:1072-1080.
66. Liu CH, Peck K, Huang JD, Lin MS, Wang CH, Hsu WP, Wang HW, Lee HL, Lai ML. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005; 6:731-747.
67. Du J, Yu L, Wang L, Zhang A, Shu A, Xu L, Xu M, Shi Y, Li X, Feng G, Xing Q, He L. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta 2007; 383:172-174.
68. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62:927-931.
69. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. J Pharmacol Exp Ther 1978; 207:92-100.
70. Wesmiller SW, Henker RA, Sereika SM, Donovan HS, Meng L, Gruen GS, Tarkin IS, Conley YP. The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients. Biol Res Nurs 2013; 15:382-389.
71. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000; 10:373-388.
72. Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
73. Zhang W, Chang YZ, Kan QC, Zhang LR, Li ZS, Lu H, Wang Z., Chu QJ, Zhang J. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. European Journal of Clinical Pharmacology 2010; 66:61-66.
74. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004; 23:100.
75. Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007; 37:315-327.
76. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138:103-141.
77. Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, Zhou HH. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clinica Chimica Acta; International Journal of Clinical Chemistry 2005; 353:187-192.
78. Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Anwar Ababneh N, Hasan F, Zaloom I, Khayat G, Al-Zmili R, Naffa R, Al-Diab O. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep 2012; 39:9423-9433.
79. Lee SJ, Lee SS, Jeong HE, Shon JH, Ryu JY, Sunwoo YE, Liu KH, Kang W, Park YJ, Shin CM, Shin JG. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos 2007; 35:2095-2101.
80. Lotsch J, Schmidt R, Vetter G, Schmidt H, Niederberger E, Geisslinger G, Tegeder I. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 2002; 83:241-248.
81. Rakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008; 4:64.
82. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-444.
83. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
84. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80:668-681.
85. Lotsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 2009; 124:168-184.
86. Sia AT, Sng BL, Lim EC, Law H, Tan EC. The influence of ATP-binding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: A prospective cohort study. Int J Obstet Anesth 2010; 19:254-260.
87. Mamie C, Rebsamen MC, Morris MA, Morabia A. First evidence of a polygenic susceptibility to pain in a pediatric cohort. Anesth Analg 2013; 116:170-177.
88. Candiotti K, Yang Z, Xue L, Zhang Y, Rodriguez Y, Wang L, Hao S, Gitlin M. Single-nucleotide polymorphism C3435T in the ABCB1 gene is associated with opioid consumption in postoperative pain. Pain Med 2013; 14:1977-1984.
89. Choi EM, Lee MG, Lee SH, Choi KW, Choi SH. Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia 2010; 65:996-1000.
90. Matouskova O, Slanar O, Adamkova J, Pafko P, Perlik F, Adamek S. Impact of MDR1 genetic polymorphisms on postoperative piritramide analgesia. Bratisl Lek Listy 2013; 114:133-135.
91. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 1992; 12:822-825.
92. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velocardio-facial syndrome. Am J Med Genet 1996; 67:468-472.
93. Mannisto PT, Kaakkola S. Catechol-Omethyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51:593-628.
94. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14:135-143.
95. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007; 128:199-208.
96. 96. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34:4202-4210.
97. Kambur O, Mannisto PT. Catechol-O-methyltransferase and pain. Int Rev Neurobiol 2010; 95:227-279.
98. van Meurs JB, Uitterlinden AG, Stolk L, Kerkhof HJ, Hofman A, Pols HA, Bierma-Zeinstra SM. A functional polymorphism in the catechol-O-methyltransferase gene is associated with osteoarthritis-related pain. Arthritis Rheum 2009; 60:628-629.
99. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB, Goldman D, Maixner W. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006; 125:216-224.
100. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003; 23:8788-8799.
101. 101. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: Guilt by association. Neuroscientist 2004; 10:575-593.
102. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: Preliminary data from a naturalistic study. Neuropsychopharmacology 2006; 31:1745-1749.
103. Serretti A, Mandelli L, Giegling I, Schneider B, Hartmann AM, Schnabel A, Maurer K, Moller HJ, Rujescu D. HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:291-299.
104. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006; 16:498-503.
105. Mico JA, Berrocoso E, Ortega-Alvaro A, Gibert-Rahola J, Rojas-Corrales MO. The role of 5-HT1A receptors in research strategy for extensive pain treatment. Curr Top Med Chem 2006; 6:1997-2003.
106. Colpaert FC. 5-HT(1A) receptor activation: New molecular and neuroadaptive mechanisms of pain relief. Curr Opin Investig Drugs 2006; 7:40-47.
107. Chen K, Yang W, Grimsby J, Shih JC. The human 5-HT2 receptor is encoded by a multiple intron-exon gene. Brain Res Mol Brain Res 1992; 14:20-26.
108. Campbell DA, Sundaramurthy D, Markham AF, Pieri LF. Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. Genet Test 1997; 1:297-299.
109. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15:473-500.
110. Abbott FV, Hong Y, Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology 1996; 35:99-110.
111. Tokunaga A, Saika M, Senba E. 5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. Pain 1998; 76:349-355.
112. Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, de Jonge S, Kruger M, Engel RR, Farber L, Pongratz DE, Ackenheil M. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999; 6:433-439.
113. Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B. Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 2001; 21:58-61.
114. 114. Saito YA, Cremonini F, Talley NJ. Association of the 1438G/A and 102T/C polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome 5-HT2A gene polymorphism in irritable bowel syndrome. J Clin Gastroenterol 2005; 39:835; author reply 835-836.
115. Aoki J, Hayashida M, Tagami M, Nagashima M, Fukuda K, Nishizawa D, Ogai Y, Kasai S, Ikeda K, Iwahashi K. Association between 5-hydroxytryptamine 2A receptor gene polymorphism and postoperative analgesic requirements after major abdominal surgery. Neurosci Lett 2010; 479:40-43.
116. Reichling DB, Green PG, Levine JD. The fundamental unit of pain is the cell. Pain 2013; 154 Suppl 1:S2-S9.
117. Dubin AE, Patapoutian A. Nociceptors: The sensors of the pain pathway. J Clin Invest 2010; 120:3760-3772.
118. Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol 2014; 13:587-599.
119. Willis WD, Jr. The role of TRPV1 receptors in pain evoked by noxious thermal and chemical stimuli. Exp Brain Res 2009; 196:5-11.
120. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389:816-824.
121. Xu H, Tian W, Fu Y, Oyama TT, Anderson S, Cohen DM. Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. Am J Physiol Renal Physiol 2007; 293:F1865-F1876.
122. Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: The challenges for therapeutic targeting. Trends Mol Med 2009; 15:14-22.
123. Bevan S, Andersson DA. TRP channel antagonists for pain – opportunities beyond TRPV1. Curr Opin Investig Drugs 2009; 10:655-663.
124. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, Levinson SR, Wolf JJ, Silos-Santiago I, Halegoua S, Mandel G. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci U S A 1997; 94:1527-1532.
125. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 1996; 379:257-262.
126. Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and downregulated after axotomy. Proc Natl Acad Sci U S A 1998; 95:8963-8968.
127. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444:894-898.
128. Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE, Meijer IA, Meury L, Mills T, Moody A, Morin ville A, Morten J, O’Donnell D, Raynoschek C, Salter H, Rouleau GA, Krupp JJ. A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet 2007; 16:2114-2121.
129. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyperor hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A 2006; 103:8245-8250.
130. Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 2005; 124:1333-1338.
131. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 2006; 52:767-774.
132. Yuan R, Zhang X, Deng Q, Si D, Wu Y, Gao F, Zhou B. Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception. Pain Med 2011; 12:1510-1514.
133. Duan G, Xiang G, Zhang X, Yuan R, Zhan H, Qi D. A single-nucleotide polymorphism in SCN9A may decrease postoperative pain sensitivity in the general population. Anesthesiology 2013; 118:436-442.
134. Laulin JP, Celerier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin administration: An apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 1999; 89:631-636.
135. White JM. Pleasure into pain: The consequences of long-term opioid use. Addict Behav 2004; 29:1311-1324.
136. Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J Neurosci 2001; 21:4074-4080.
137. Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell RM, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R. Adult cancer pain. J Natl Compr Canc Netw 2013; 11:992-1022.
138. Song Z, Du B, Wang K, Shi X. Effects of OPRM1 A118G polymorphism on epidural analgesia with fentanyl during labor: A meta-analysis. Genet Test Mol Biomarkers 2013; 17:743-749.
139. 139. Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda K, Liao Q. OPRM1 A118G gene variant and postoperative opioid requirement: A systematic review and meta-analysis. Anesthesiology 2014; 121:825-834.
140. Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004; 89:553-560.
141. Margas W, Zubkoff I, Schuler HG, Janicki PK, Ruiz-Velasco V. Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. J Neurophysiol 2007; 97:1058-1067.
142. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280:32618-32624.
143. Elmer GI, Pieper JO, Negus SS, Woods JH. Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests. Pain 1998; 75:129-140.
144. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M. Heritability of nociception II. ‘Types’ of nociception revealed by genetic correlation analysis. Pain 1999; 80:83-93.
145. Mogil JS, Sternberg WF, Marek P, Sadowski B, Belknap JK, Liebeskind JC. The genetics of pain and pain inhibition. Proc Natl Acad Sci U S A 1996; 93:3048-3055.
146. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16:625-636.
147. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 2003; 99:788-798.
148. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12:3-9.
149. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73:107-121.
150. Yang JC, Clark WC, Tsui SL, Ng KF, Clark SB. Preoperative Multidimensional Affect and Pain Survey (MAPS) scores predict postcolectomy analgesia requirement. Clin J Pain 2000; 16:314-320.
151. Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg 2011; 112:448-453.